Despite the lack of confidence in nanotechnologies from some quarters of the VC community, nanotech is attracting funding. Just as the Bourne Report reported a fall in investment in the first half of 2006, James Baker’s NanoBio Corporation pulled in $30m (though spread over two stages).
Rather than being an example of the pull of nanotechnologies, it is more an example of how once Biotech products get through Phase II clinical trials there is a huge increase in both value and investor interest.